)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cyxone
Cyxone (CYXO) investor relations material
Cyxone has been delisted
Cyxone Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary29 Aug, 2024
Executive summary
Focus on advancing rabeximod (Phase 2 for RA) and T20K (early clinical for MS), aiming for cost-effective development and key milestones to attract partners.
New CEO Kjell Stenberg and interim CFO Henrik Hang appointed; Maarten Kraan joined as board member.
Rights issue completed in August, raising approximately SEK 6.4 million to fund prioritized studies.
Financial highlights
Net sales remained at SEK 0.0 million for Q2 2024, unchanged year-over-year.
Operating loss for Q2 2024 was SEK -4.7 million, compared to SEK -4.9 million in Q2 2023.
Cash and cash equivalents at period end were SEK 6.3 million, down from SEK 15.1 million a year earlier.
Equity at period end was SEK 29.6 million, compared to SEK 36.8 million in Q2 2023.
Cash flow from operations for Q2 2024 was SEK -4.8 million, improved from SEK -5.5 million in Q2 2023.
Outlook and guidance
Proceeds from the rights issue will be used for prioritized studies in rabeximod and T20K.
Updated development plans and operational efficiency measures are underway.
Long-term goal is to secure partnerships or buyers for projects after Phase 2 studies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Cyxone
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cyxone is a Swedish biotechnology company focused on developing innovative treatments for autoimmune and immune-related diseases. The company's research and development efforts center on creating therapies that modulate the immune system to treat conditions such as rheumatoid arthritis and multiple sclerosis. The company is headquartered in Malmö, Sweden, and its shares are listed on the Stockholm Stock Exchange.